Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + immune checkpoint inhibitor + pemetrexed vs platinum + immune checkpoint inhibitor + pemetrexed in elderly HIV-positive stage IV non-squamous NSCLC
ChiCTR2600126902Phase 2Not yet recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab and pemetrexed in non-small cell lung cancer (NSCLC) and human immunodeficiency virus infection (HIV) (2 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoints: 24-week progression-free survival (PFS), HIV-related markers and 4 more. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
bevacizumabpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ChiCTR2600126902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126902.